CYH
Community Health Systems, Inc.
CYH trails on the overall score without a compensating advantage in the available component scores.
OSCR
Oscar Health, Inc.
OSCR has the edge over CYH overall, supported by lower modeled downside and stronger modeled upside.
CYH Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Under pressure | |
| Weak |
CYH's profitability is currently stable, but its revenue, cash flow and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CYH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 1.3x | $0.35 | -84% |
| Fair | 2x | $0.55 | -75% |
| Expensive | 4.4x | $1.18 | -47% |
| Current | 8.2x | $2.21 | — |
Historical ranges are pointers, not guarantees.
CYH's PE is in its expensive range at 8.2x.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over CYH in the historical PE scenario, which offers more potential upside but is not a forecast.
CYH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Stable | |
| Limited | |
| Low |
Analysts expect CYH's losses to grow, with revenue declining. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over CYH on the outlook, with more favorable earnings and revenue expectations.
CYH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.27 | -89% |
| Q2 2026 | $1.86 | +$3.35 |
| Q1 2026 | $3.44 | +$7.12 |
| Q4 2025 | $3.77 | +$7.67 |
| Q3 2025 | $2.42 | +$5.43 |
| Q2 2025 | -$1.49 | -$0.74 |
| Q1 2025 | -$3.68 | -$2.74 |
| Q4 2024 | -$3.90 | -$2.88 |
CYH's earnings per share have fallen from their peak: $0.27 over the past year, against $4.39 in late 2020.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
CYH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.8B | -11% |
| Q2 2026 | $2.8B | -9.8% |
| Q1 2026 | $3B | -6.1% |
| Q4 2025 | $3.1B | -4.9% |
| Q3 2025 | $3.1B | -0.1% |
| Q2 2025 | $3.1B | -0.2% |
| Q1 2025 | $3.2B | +0.6% |
| Q4 2024 | $3.3B | +2.6% |
CYH's revenue has slid since its 2019 peak: $2.8B last quarter, down 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.3% | -2.6 points |
| Q2 2026 | 14% | -2.6 points |
| Q1 2026 | 9.5% | +0.5 points |
| Q4 2025 | 14% | +6 points |
| Q3 2025 | 7.9% | +15 points |
| Q2 2025 | 16% | +8.8 points |
| Q1 2025 | 9% | +1.6 points |
| Q4 2024 | 8.5% | -1.8 points |
CYH has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CYH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
CYH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $67M | +1575% |
| Q2 2026 | $12M | +$15M |
| Q1 2026 | -$373M | -1166% |
| Q4 2025 | $172M | +61% |
| Q3 2025 | $4M | +$7M |
| Q2 2025 | -$3M | -123% |
| Q1 2025 | $35M | +1067% |
| Q4 2024 | $107M | +$127M |
CYH's free cash flow was −$122M over the past year, against $143M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CYH on cash generation, producing positive trailing cash flow while its opponent burns cash.
CYH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -963K shares |
| 1 year | +0.3% | +355K shares |
| 3 years | +3.7% | +4.8M shares |
| 5 years | +3.6% | +4.7M shares |
| Available history | +19% | +21.6M shares |
CYH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CYH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.5x | High |
| Q2 2026 | 5.2x | High |
| Q1 2026 | 4.9x | High |
| Q4 2025 | 5.3x | High |
| Q3 2025 | 5.9x | High |
| Q2 2025 | 7.9x | High |
| Q1 2025 | 10.2x | High |
| Q4 2024 | 11.1x | High |
CYH's net debt is about 5.5 years of its operating earnings (EBITDA), down from 5.9 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over CYH on leverage, with a lower net debt burden relative to earnings.
CYH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.4 | Neutral |
| Stochastic | 19.0 | Oversold |
CYH's weekly RSI is 34 (neutral) and its Stochastic is 19 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CYH PE vs Healthcare Sector
| Metric | CYH | Sector median | Relative |
|---|---|---|---|
| PE | 8.2x | 26x | 68% below |
| PE % | 92 | 29 | 63 pts above |
CYH has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CYH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.63 | 16% below |
| 20 week MA | $2.90 | 24% below |
| 50 week MA | $3.03 | 27% below |
| 100 week MA | $3.09 | 28% below |
| 200 week MA | $3.55 | 38% below |
CYH is in a downtrend: it's below all five of its weekly moving averages, and 38% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CYH on trend strength, trading above more of its moving averages.
CYH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.77 | $7.67 | +177% |
| 2021 | $7.67 | $13.3 | +73% |
| 2022 | $13.3 | $3.88 | -71% |
| 2023 | $3.88 | $3.13 | -19% |
| 2024 | $3.13 | $3.03 | -3.2% |
| 2025 | $3.03 | $3.23 | +6.6% |
| 2026 YTD | $3.23 | $2.21 | -32% |
CYH's yearly returns have swung widely, from +177% in 2020 to −71% in 2022. It's down 32% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CYH on returns for 2026, with the stronger performance.